Theradaptive Receives FDA Approval to Advance OsteoAdapt SP to Pivotal Phase 3 Trial for Spinal Fusion
Key Insights
Theradaptive (search) has secured FDA approval to initiate a pivotal Phase 3 clinical trial evaluating OsteoAdapt SP (search), a next-generation bone regeneration therapy for spinal fusion procedures.
The OASIS trial will evaluate OsteoAdapt SP (search) as an alternative to autologous and allograft bone grafts across three major spinal fusion procedures for degenerative lumbosacral spine diseases.
The approval builds on successful treatment of approximately 100 participants in earlier clinical studies and represents a significant step toward FDA premarket approval and U.S. commercialization.
Theradaptive (search), Inc., a clinical-stage biotechnology company, has received U.S. Food and Drug Administration approval to initiate a pivotal Phase 3 clinical trial evaluating OsteoAdapt SP (search), its investigational regenerative therapeutic for spinal fusion procedures. The FDA authorization represents a critical milestone for advancing next-generation bone regeneration therapy for patients with degenerative spinal diseases (search).
OASIS Trial Design and Scope
The OASIS trial will evaluate OsteoAdapt SP (search) as an alternative to autologous and allograft bone grafts in single-level spinal fusion procedures. The study encompasses three major surgical approaches: Transforaminal Lumbar Interbody Fusion (TLIF), Anterior Lumbar Interbody Fusion (ALIF), and Lateral Lumbar Interbody Fusion (LLIF) procedures for treating symptomatic degenerative diseases of the lumbosacral spine.
Theradaptive (search) is the only advanced therapeutics company conducting investigational device exemption (IDE) studies with indications across all three surgical approaches, positioning the company to address the majority of spinal fusion needs. The trial was developed using technology licensed from the DHA Office of Medical Technology Transfer (search).
Clinical Foundation and Development Path
The approval builds on a robust clinical foundation, including the successful treatment of approximately 100 participants in earlier clinical experience. The company has expanded enrollment across sites in Australia and Israel, demonstrating international clinical development capabilities.
"Receiving authorization to initiate our pivotal Phase 3 trial is a defining milestone for Theradaptive (search) and an important step toward delivering a much-needed solution for patients living with degenerative spinal conditions (search)," said Dr. Luis Alvarez, Founder and CEO of Theradaptive. "Our focus is now on disciplined clinical execution and close collaboration with leading investigators to generate the high-quality data needed to advance this field and improve patient outcomes."
The advancement to pivotal study marks a significant step toward FDA premarket approval (PMA) and U.S. commercialization of OsteoAdapt SP (search).
Market Opportunity and Unmet Medical Need
Degenerative spinal conditions (search) represent a substantial healthcare burden, with 80% of American adults experiencing low back pain (search) in their lifetime and nearly one in three living with a diagnosed degenerative spinal condition. As the population ages, prevalence is expected to continue rising, driving demand for safer, more effective, and innovative treatments.
The global bone graft substitute segment represents a significant and expanding market, currently valued at over $3 billion and projected to exceed $5 billion by the early 2030s. For nearly 25 years, the recombinant protein segment has been dominated by a single commercialized legacy product, which achieved peak annual revenues nearing $900 million.
AMP2 Technology Platform
OsteoAdapt SP (search) is powered by AMP2, a proprietary rhBMP-2 variant engineered to promote targeted, sustained bone regeneration. The technology is designed to minimize off-target effects and address key limitations of current graft materials, aiming to meaningfully improve both the safety and efficacy of spinal fusion procedures.
The therapeutic represents Theradaptive (search)'s lead investigational device, though it remains limited by U.S. Federal law to investigational use only and is not approved for commercial sale.
Company Profile
Theradaptive (search) is a privately held, clinical-stage biologics company developing protein therapeutics for spine, orthopedics, dental, and soft tissue repair, as well as targeted therapeutics in areas such as immuno-oncology. The company leverages its therapeutic delivery platform to deliver recombinant biologics to targeted areas in the body with high precision and persistence to address unmet medical needs.
The development work has been supported by the Assistant Secretary of Defense for Health Affairs in the Department of Defense, through the Peer Reviewed Medical Research Program under Award No. HT9425-23-1-0693.